Decentralized trial solutions for complex clinical trials
Improving the patient experience while overcoming DCT challenges for a pediatric rare disease population
Making decentralized clinical trials a successful reality for the most complex studies is considered challenging, but not impossible. While the industry is finally adopting decentralized clinical trial (DCT) solutions, they are considered to be quite difficult to conduct given the many logistical and data collection challenges for therapeutics that target complex and rare diseases in narrowly defined patient populations.
Veristat shares their expertise and lessons learned from conducting a natural history study for a rare pediatric disease, which not only included virtual components from the start, but had to pivot mid-way to add in additional virtual visits during the pandemic lockdowns. This case study illustrates the challenges and flexible solutions that ensured the continued success of the study. Join us as we share the strategies that were deployed to improve the patient experience.
